Drug intelligence / Profile preview

bravecto quantum

Development stage
Unknown
Lead developer
Merck Animal Health
Modality
Small Molecules
Administration
Subcutaneous
01

Overview

**Bravecto Quantum (fluralaner for extended-release injectable suspension)** is a long-acting parasiticide for dogs indicated for the treatment and prevention of flea infestations (Ctenocephalides felis) and the treatment and control of tick infestations, specifically Ixodes scapularis (black-legged tick), Dermacentor variabilis (American dog tick), Rhipicephalus sanguineus (brown dog tick) for 12 months, and Amblyomma americanum (lone star tick) for 8 months in dogs and puppies 6 months of age and older[1][3][13]. The active ingredient, fluralaner, is an isoxazoline-class agent that inhibits arthropod nervous system function by targeting gamma-aminobutyric acid (GABA)- and glutamate-gated chloride channels, leading to paralysis and death of fleas and ticks[2]. It is administered as a single subcutaneous injection. The unique extended-release formulation provides continuous efficacy for up to a year, reducing the need for monthly or spot-on treatments[3][6]. Side effects are uncommon but may include mild, temporary injection site reactions, and very rarely neurologic adverse events such as seizures[7].

Brand names
Bravecto Quantum
Other names
Bravecto QuantumBravecto (for reference; original chewable/spot-on formulations)
02

Targets

RDL (Insect GABA-gated chloride channel)GluCl (Glutamate-gated chloride channel)

Beyond the preview

Go deeper on bravecto quantum.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on bravecto quantum.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call